AVNS Share Price | Avanos Medical, Inc. Stock Analysis & Recommendation

Q: What does Avanos Medical, Inc. do?

Overview: Avanos Medical, Inc. is a medical technology company that provides a portfolio of product offerings focused on surgical and interventional pain management, respiratory and digestive health, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.Financial Snapshot: Most recent Net Sales: 168 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 7 Million (Quarterly Results - Mar 2025) Market cap: USD 564.21 Million (Micro Cap)Key Metrics: P/E: 9.00 Dividend Yield: 0.00% Debt Equity: 0.02 Return on Equity: 7.63% Price to Book: 0.67Contact Details: Address: 5405 Windward Parkway, ALPHARETTA GA : 30004 Tel: 1 678 4259273 Website: https://avanos.com/

Q: Is Avanos Medical, Inc. overvalued or undervalued?

As of 26 February 2025, the valuation grade for Avanos Medical, Inc. has moved from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued based on its current metrics, with a P/E ratio of 9, an EV to EBITDA of 6.23, and a PEG ratio of 0.12, which suggests that despite a low valuation in terms of earnings, the growth prospects may not justify the current price. In comparison to peers, Avanos Medical's P/E ratio of 9.80 is higher than that of Paragon 28, Inc. at -20.38, but lower than Myriad Genetics, Inc. at -11.75, indicating that while it is relatively better positioned, the overall industry sentiment remains negative. The company's stock has underperformed significantly against the S&P 500, with a 1-year return of -49.28% compared to the index's 17.14%, reinforcing the notion of overvaluation amidst a challenging market environment.

Q: Is Avanos Medical, Inc. technically bullish or bearish?

As of 26 September 2025, the technical trend for Avanos Medical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages and the weekly Dow Theory, both indicating a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe, but is bearish on the monthly, while the RSI is bullish monthly but has no signal weekly. Bollinger Bands are bearish on both weekly and monthly timeframes. In terms of performance, Avanos has underperformed the S&P 500 significantly over multiple periods, with a year-to-date return of -26.07% compared to the S&P 500's 12.96%, and a one-year return of -49.89% versus 15.64% for the benchmark.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

182.6 k

Shareholding (Dec 2025)

FII

8.09%

Held by 93 FIIs

DII

40.95%

Held by 57 DIIs

Promoter

0.36%

How big is Avanos Medical, Inc.?

22-Jun-2025

As of Jun 18, Avanos Medical, Inc. has a market capitalization of 564.21 million and reported net sales of 689.20 million, with a net profit loss of 380.20 million over the latest four quarters. Shareholder's funds are at 828.50 million, and total assets amount to 1,154.20 million.

View full answer

What does Avanos Medical, Inc. do?

22-Jun-2025

Avanos Medical, Inc. is a medical technology company specializing in surgical and interventional pain management, as well as respiratory and digestive health. As of March 2025, it reported net sales of $168 million and a market cap of $564.21 million.

View full answer

Who are in the management team of Avanos Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Avanos Medical, Inc. includes Chairman Gary Blackford, CEO Joseph Woody, and several independent directors: John Byrnes, William Hawkins, Heidi Kunz, Patrick O'Leary, and Maria Sainz. They oversee the company's operations and strategic direction.

View full answer

Is Avanos Medical, Inc. overvalued or undervalued?

20-Sep-2025

As of February 26, 2025, Avanos Medical, Inc. is considered a risky investment due to its overvaluation, reflected in a P/E ratio of 9, an EV to EBITDA of 6.23, and a significant underperformance of -49.28% over the past year compared to the S&P 500's 17.14% return.

View full answer

Is Avanos Medical, Inc. technically bullish or bearish?

30-Sep-2025

As of September 26, 2025, Avanos Medical, Inc. has a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -26.07% versus 12.96% for the index.

View full answer

Compare Avanos Medical, Inc. with Similar Stocks

Paragon 28, Inc.Quanterix Corp.Stevanato Group SpA

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor Management Efficiency with a low ROCE of 5.39%

The company has been able to generate a Return on Capital Employed (avg) of 5.39% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of -0.37% over the last 5 years

Flat results in Jun 25

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 646 Million (Micro Cap)

P/E

11.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.05

Return on Equity

7.62%

Price to Book

0.83

Revenue and Profits:

Net Sales:

181 Million

(Quarterly Results - Dec 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

18.93%

6 Months

16.23%

1 Year

-4.43%

2 Years

-27.61%

3 Years

-50.82%

4 Years

-57.07%

5 Years

-71.27%

Avanos Medical, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-0.55%

EBIT Growth (5y)

-6.38%

EBIT to Interest (avg)

7.55

Debt to EBITDA (avg)

0.93

Net Debt to Equity (avg)

0.02

Sales to Capital Employed (avg)

0.60

Tax Ratio

3.77%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

5.39%

ROE (avg)

4.86%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.83

EV to EBIT

17.11

EV to EBITDA

8.56

EV to Capital Employed

0.84

EV to Sales

0.98

PEG Ratio

0.23

Dividend Yield

ROCE (Latest)

4.90%

ROE (Latest)

7.62%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 63 Schemes (50.53%)

Foreign Institutions

Held by 93 Foreign Institutions (8.09%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 1.74% vs 1.60% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 7.14% vs 98.18% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "180.90",
          "val2": "177.80",
          "chgp": "1.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "12.10",
          "val2": "22.50",
          "chgp": "-46.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "1.80",
          "chgp": "5.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "-10.70",
          "chgp": "89.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.30",
          "val2": "-1.40",
          "chgp": "7.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.20%",
          "val2": "73.70%",
          "chgp": "-6.15%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1.95% vs 2.15% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 81.13% vs -3,802.02% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "701.20",
          "val2": "687.80",
          "chgp": "1.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "54.00",
          "val2": "85.50",
          "chgp": "-36.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.80",
          "val2": "12.20",
          "chgp": "-36.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-77.10",
          "val2": "-440.10",
          "chgp": "82.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-72.90",
          "val2": "-386.30",
          "chgp": "81.13%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "21.50%",
          "val2": "58.20%",
          "chgp": "-3.67%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

180.90

177.80

1.74%

Operating Profit (PBDIT) excl Other Income

12.10

22.50

-46.22%

Interest

1.90

1.80

5.56%

Exceptional Items

-1.10

-10.70

89.72%

Consolidate Net Profit

-1.30

-1.40

7.14%

Operating Profit Margin (Excl OI)

12.20%

73.70%

-6.15%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 1.74% vs 1.60% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 7.14% vs 98.18% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

701.20

687.80

1.95%

Operating Profit (PBDIT) excl Other Income

54.00

85.50

-36.84%

Interest

7.80

12.20

-36.07%

Exceptional Items

-77.10

-440.10

82.48%

Consolidate Net Profit

-72.90

-386.30

81.13%

Operating Profit Margin (Excl OI)

21.50%

58.20%

-3.67%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 1.95% vs 2.15% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 81.13% vs -3,802.02% in Dec 2024

All Annual Results

Company CV

About Avanos Medical, Inc.

Avanos Medical, Inc.

Pharmaceuticals & Biotechnology

Avanos Medical, Inc., formerly Halyard Health, Inc., is a medical technology company. The Company provides a portfolio of product offerings focused on surgical and interventional pain management, respiratory and digestive health. Its products include post-operative pain management solutions, minimally invasive interventional or chronic pain therapies, closed airway suction systems and enteral feeding tubes. The company’s products are sold under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, QUIKBLOC, HOMEPUMP, CORTRAK and other brand names.

Company Coordinates

Company Details

5405 Windward Parkway , ALPHARETTA GA : 30004

Tel: 1 678 4259273

https://avanos.com/

Registrar Details